期刊
HEMOGLOBIN
卷 32, 期 1-2, 页码 229-236出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/03630260701680367
关键词
pharmacogenomics; pharmacogenetics; beta-thalassemia (thal); sickle cell disease; genotyping; single nucleotide polymorphisms (SNPs)
资金
- NHLBI NIH HHS [5R01HL73455-02] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073455] Funding Source: NIH RePORTER
Individual genetic constitution is an important cause of variations in the response and tolerance to drug treatment. Single nucleotide polymorphisms (SNPs) in genes located within as well as outside the human beta-globin cluster have recently been shown to be significantly associated with Hb F increase in relation to hydroxyurea (HU) treatment in hemoglobinopathies patients. This article provides an update and discusses future challenges on the application of pharmacogenetic testing and pharmacogenomics for hemoglobinopathies therapeutics in relation to the current pharmacological treatment modalities for those disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据